PCM
CSTL icon

Penserra Capital Management’s Castle Biosciences CSTL Stock Holding History

Penserra Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-575
Closed -$38K – 1407
2021
Q3 		$38K Buy
575
+5
+0.9% +$352 ﹤0.01% 1126
2021
Q2 		$41K Buy
570
+15
+3% +$991 ﹤0.01% 1042
2021
Q1 		$37K Buy
555
+95
+21% +$7.14K ﹤0.01% 867
2020
Q4 		$30K Buy
460
+292
+174% +$15.8K ﹤0.01% 778
2020
Q3 		$8K Buy
+168
New +$7.47K ﹤0.01% 833

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Penserra Capital Management's CSTL Position: Q4 2021 in Review

Penserra Capital Management sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 575 shares — an estimated $38K sold.

Penserra Capital Management first reported a position in CSTL in Q3 2020 and held it in 5 quarters. The position peaked at $41K in Q2 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • Penserra Capital Management reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 575 Castle Biosciences shares in Q4 2021, an estimated $38K.
  • Penserra Capital Management first reported a position in Castle Biosciences in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Castle Biosciences position peaked at $41K in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.